Eli Lilly and Company (NYSE:LLY) Shares Bought by Providence Capital Advisors LLC

Providence Capital Advisors LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 3.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 507 shares of the company’s stock after purchasing an additional 17 shares during the quarter. Providence Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $391,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $8,407,908,000. Caisse Des Depots ET Consignations bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth $6,753,000. LM Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 25.7% in the fourth quarter. LM Advisors LLC now owns 6,138 shares of the company’s stock valued at $4,739,000 after buying an additional 1,254 shares during the period. Loomis Sayles & Co. L P boosted its stake in Eli Lilly and Company by 19.2% during the fourth quarter. Loomis Sayles & Co. L P now owns 2,227 shares of the company’s stock valued at $1,719,000 after buying an additional 358 shares in the last quarter. Finally, AssuredPartners Investment Advisors LLC bought a new position in Eli Lilly and Company during the fourth quarter valued at about $1,583,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on LLY. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. Morgan Stanley set a $1,146.00 target price on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Citigroup decreased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Finally, Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Stock Down 0.6 %

Shares of Eli Lilly and Company stock opened at $822.14 on Friday. The firm has a market cap of $779.52 billion, a price-to-earnings ratio of 70.21, a P/E/G ratio of 1.40 and a beta of 0.34. The stock has a 50-day simple moving average of $842.43 and a 200-day simple moving average of $837.43. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has approved a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.